Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay

被引:141
作者
Perreard, L
Fan, C
Quackenbush, JF
Mullins, M
Gauthier, NP
Nelson, E
Mone, M
Hansen, H
Buys, SS
Rasmussen, K
Orrico, AR
Dreher, D
Walters, R
Parker, J
Hu, ZY
He, XP
Palazzo, JP
Olopade, OI
Szabo, A
Perou, CM
Bernard, PS [1 ]
机构
[1] ARUP Inst Clin & Expt Pathol, Salt Lake City, UT USA
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pathol & Lab Sci, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Dept Genet, Chapel Hill, NC USA
[4] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA
[5] Univ Utah, Sch Med, Dept Surg, Salt Lake City, UT USA
[6] Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT USA
[7] Maine Ctr Canc Med, Dept Clin Genet, Scarborough, ME USA
[8] Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA
[9] Constella Hlth Sci, Durham, NC USA
[10] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[11] Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT USA
关键词
D O I
10.1186/bcr1399
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Predicting the clinical course of breast cancer is often difficult because it is a diverse disease comprised of many biological subtypes. Gene expression profiling by microarray analysis has identified breast cancer signatures that are important for prognosis and treatment. In the current article, we use microarray analysis and a real-time quantitative reverse-transcription (qRT)-PCR assay to risk-stratify breast cancers based on biological 'intrinsic' subtypes and proliferation. Methods Gene sets were selected from microarray data to assess proliferation and to classify breast cancers into four different molecular subtypes, designated Luminal, Normal-like, HER2+/ER-, and Basal-like. One-hundred and twenty-three breast samples (117 invasive carcinomas, one fibroadenoma and five normal tissues) and three breast cancer cell lines were prospectively analyzed using a microarray (Agilent) and a qRT-PCR assay comprised of 53 genes. Biological subtypes were assigned from the microarray and qRT-PCR data by hierarchical clustering. A proliferation signature was used as a single meta-gene (log(2) average of 14 genes) to predict outcome within the context of estrogen receptor status and biological 'intrinsic' subtype. Results We found that the qRT-PCR assay could determine the intrinsic subtype (93% concordance with microarray-based assignments) and that the intrinsic subtypes were predictive of outcome. The proliferation meta-gene provided additional prognostic information for patients with the Luminal subtype (P=0.0012), and for patients with estrogen receptor-positive tumors (P=3.4x10(-6)). High proliferation in the Luminal subtype conferred a 19-fold relative risk of relapse (confidence interval=95%) compared with Luminal tumors with low proliferation. Conclusion A real-time qRT-PCR assay can recapitulate microarray classifications of breast cancer and can risk-stratify patients using the intrinsic subtype and proliferation. The proliferation meta-gene offers an objective and quantitative measurement for grade and adds significant prognostic information to the biological subtypes.
引用
收藏
页数:11
相关论文
共 35 条
[1]  
[Anonymous], 1998, INTRO BOOTSTRAP
[2]   Semi-supervised methods to predict patient survival from gene expression data [J].
Bair, E ;
Tibshirani, R .
PLOS BIOLOGY, 2004, 2 (04) :511-522
[3]   Adjustment of systematic microarray data biases [J].
Benito, M ;
Parker, J ;
Du, Q ;
Wu, JY ;
Xang, D ;
Perou, CM ;
Marron, JS .
BIOINFORMATICS, 2004, 20 (01) :105-114
[4]   Current perspectives on HER2 testing:: A review of national testing guidelines [J].
Bilous, M ;
Dowsett, M ;
Hanna, W ;
Isola, J ;
Lebeau, A ;
Moreno, A ;
Penault-Llorca, F ;
Rüschoff, J ;
Tomasic, G ;
de Vijver, MV .
MODERN PATHOLOGY, 2003, 16 (02) :173-182
[5]   Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia [J].
Bullinger, L ;
Döhner, K ;
Bair, E ;
Fröhling, S ;
Schlenk, RF ;
Tibshirani, R ;
Döhner, H ;
Pollack, JR .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (16) :1605-1616
[6]   Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival [J].
Chang, HY ;
Nuyten, DSA ;
Sneddon, JB ;
Hastie, T ;
Tibshirani, R ;
Sorlie, T ;
Dai, HY ;
He, YDD ;
van't Veer, LJ ;
Bartelink, H ;
van de Rijn, M ;
Brown, PO ;
van de Vijver, MJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (10) :3738-3743
[7]   Measurement of gene expression in archival paraffin-embedded tissues - Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay [J].
Cronin, M ;
Pho, M ;
Dutta, D ;
Stephans, JC ;
Shak, S ;
Kiefer, MC ;
Esteban, JM ;
Baker, JB .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 164 (01) :35-42
[8]   A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients [J].
Dai, HY ;
van't Veer, L ;
Lamb, J ;
He, YD ;
Mao, M ;
Fine, BM ;
Bernards, R ;
de Vijver, MV ;
Deutsch, P ;
Sachs, A ;
Stoughton, R ;
Friend, S .
CANCER RESEARCH, 2005, 65 (10) :4059-4066
[9]   SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data [J].
Diehn, M ;
Sherlock, G ;
Binkley, G ;
Jin, H ;
Matese, JC ;
Hernandez-Boussard, T ;
Rees, CA ;
Cherry, JM ;
Botstein, D ;
Brown, PO ;
Alizadeh, AA .
NUCLEIC ACIDS RESEARCH, 2003, 31 (01) :219-223
[10]  
Dudoit S, 2002, GENOME BIOL, V3